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Saudi Journal of Ophthalmology (2012) 26, 117–123Ophthalmic Pathology UpdateFine needle aspiration biopsy of ophthalmic tumorsqArun D. Singh, MD a,⇑; Charles V. Biscotti, MD bAbstractA majority of intraocular tumors can be diagnosed based on clinical examination and ocular imaging studies, which obviate the
need for diagnostic ophthalmic fine needle aspiration biopsy (FNAB). Overall, diagnostic accuracy of ophthalmic FNAB is high
but limited cellularity can compromise the diagnostic potential of ophthalmic aspirate samples. The role of ophthalmic FNAB is
limited in retinal tumors. Orbital FNAB should be considered in the evaluation of lacrimal gland tumors, orbital metastasis, and
lymphoproliferative lesions. Negative cytologic diagnosis of malignancy should not be considered unequivocal proof that an intra-
ocular malignancy does not exist. With improved understanding of genetic prognostic factors of uveal melanoma, ophthalmic
FNAB is gaining popularity for prognostic purposes in combination with eye conserving treatment of the primary tumor. In special
clinical indications, ancillary studies such as immunohistochemistry and FISH can be performed on ophthalmic FNAB samples.
Assistance of an experienced cytopathologist cannot be overemphasized.
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Fine needle aspiration biopsy (FNAB) of ophthalmic
tumors is being increasingly performed.1–5 In this article we
discuss indications, techniques, complications, and the limita-
tions of the ophthalmic FNAB.History
Although relatively recently accepted in the evaluation of
ophthalmic tumors, FNAB of tumors has a long history.
6–11 The first intraocular biopsy was performed by Hirschberg
in 1868.2,12–17 In 1979, Jakobiec published a major report on
the use of FNAB for the diagnosis of intraocular tumors.18
Since then others have reported on safety and reliability of
ophthalmic FNAB19–25 with adequacy rates of 88–95%.23,26Peer review under responsibility
of Saudi Ophthalmological Society,
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The technique and instrumentation for FNAB vary
depending upon the involved tissue (retina, choroid, subret-
inal space, vitreous, and aqueous),27,28 suspected diagnosis,
size, location, associated retinal detachment, and clarity of
the media.25,29–35,5
Most frequently used needles for ophthalmic FNAB are of
25–30 gauge (Fig. 1).5 Likelihood of insufficient samples may
be lower with a 22 gauge needle36 and higher with a 30
gauge needle.37 Some authors have recommended bending
the needle tip to 90 degrees and entering the tumor tangen-
tially rather than radially.35 A prototype needle with a short
bevel and mm graduations has also become available.38 Spe-
cifically designed intraocular forceps to retrieve tumor sam-
ple through retinotomy (Essen Forceps) allows histological
and immunohistochemistry typing.39j Production and hosting by ElsevierAccess this article online: www.saudiophthaljournal.comwww.sciencedirect.com
ary 2012.
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Figure 1. A short 25 gauge needle attached to short tubing is inserted through the scleral bed into the tumor and aspiration performed (A). The aspirate
sample is placed in a preservative solution, such as CytoLyt and the needle rinsed to optimize cell yield (B). Reproduced with permission from: Singh
AD, Pelayes DE, Brainard JA, Biscotti CV. History, indications, techniques and limitations. Monographs in clinical cytology 2012; 21: 1–9.5
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In the case of iris tumors the entry is through the anterior
chamber.40 A 26–30 gauge needle is swept over the surface
of the lesion aspirating about 0.5 ml of the aqueous humor.40
Direct insertion of the needle into the tumor may increase the
cellular yield.41 Complications such as persistent hyphema,
prolonged hypotony, lens damage or endophthalmitis are
rarely observed (<1%).41
Ciliary body and pre equatorial tumors
Tumors located in the ciliary body or anterior choroid are
approached trans-sclerally. A 3-mm square scleral flap to a
depth of approximately 80% is fashioned. A short 25 gauge
needle attached to short tubing is inserted through the
scleral bed.
Post equatorial tumors
Posterior choroidal tumors are most accessible by a trans-
vitreal approach. A 25–30 gauge needle attached to a 5 ml
syringe by a short tubing is introduced into the mid vitreous
cavity through parsplana 4 mm behind the limbus. The merid-
ian of insertion is selected based upon the location of the tu-
mor. The needle can be guided into the tumor either under
indirect ophthalmolscopic control or a microscope depend-
ing upon the surgeon’s preference.35 Ultrasonic guidance is
rarely used in the presence of a clear media.18 The needle
tip is inserted into the tumor avoiding major retinal or tumor
vessels. Gentle aspiration is performed by pulling the plun-
ger. Once the suction force has balanced out the needle is
withdrawn along the path of insertion.35 Localised subretinal
and/or vitreous hemorrhage is controlled by applying pres-
sure at the entry site by a cotton tipped applicator.33,35–37 Ifthe globe softens, balanced salt solution can be injected into
the vitreous cavity.
Sample handling
At our institution, we use the ThinPrep processing system
for ophthalmic FNAB samples. We place all material in Cyto-
lyt solution for ThinPrep processing (Fig. 1).42 The sample in
Cytolyt is then subjected to one or more centrifugation and
concentration steps (Fig. 2).42 The pellet obtained is resus-
pended in a cell preservative solution, PreservCyt for auto-
mated processing. The ThinPrep processor mixes the
sample and then, using a gentle vacuum, collects cells on a
filter in a monolayer. This filter is then inverted and its cellular
contents transferred to a microscope slide. This method opti-
mizes cell yield and preservation and standardizes slide prep-
aration for interpretation in this setting of limited material. If
abundant aspirate material is obtained, paraffin-embedded
cell block can be processed. While we rarely perform immu-
nostains on preparations other than a cell block, some
authors have reported successful immunohistochemical anal-
yses on thin layer cytology preparations.25,42–44
Indications
The major indication for ophthalmic FNAB is when clinical
examination and ancillary testing fail to establish an accurate
diagnosis.23,25,43,45 Potential scenarios include those with
atypical clinical presentation, dense media opacity, possible
uveal metastasis without known primary tumor, and patients
requesting histopathologic confirmation before undergoing
recommended therapy such as enucleation.35 In our experi-
ence, ophthalmic FNAB is an effective technique to confirm
a clinical diagnosis of malignancy including uveal metastasis
and uveal melanoma.5,21
Figure 2. Automated ThinPrep processing. The Thin Prep filter rotates in the sample separating cellular material from background debris. A vacuum
collects cells on the exterior surface of the filter membrane. The filter is then inverted and gently pressed against the ThinPrep slide. Surface tension and
air pressure cause the cells to adhere to the slide, resulting in even distribution of cells in a central circular region of a slide. Reproduced with permission
from: Brainard JA, Biscotti CV. Cytological preparation. Monographs in clinical cytology 2012; 21: 10–6.42
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Shields and associates have reported on the diagnostic
effectiveness of intraocular FNAB on 140 patients with
intraocular malignancies such as uveal melanoma, uveal
metastasis, retinoblastoma, lymphoma, and leukemia
(Fig. 3).23,46 Histologic correlation was available in 57 of
cases; with histology–cytology diagnostic concordance in
54 of 57 (95%) cases. Augsburger and colleagues examined
71 ophthalmic FNA samples.21 Histologic correlation was
available for 9 of those and the cytologic diagnoses were
confirmed in 8 out of 9 cases. In addition, all 11 aspirates
done to confirm benign conditions were read as benign.21Nevus vs melanoma (indeterminate
melanocytic lesions)
Given that cellular yield is lower with smaller tumors45,47,48
and even an expert cytopathologist may not be able to
unequivocally distinguish a nevus from melanoma,25 we feel
that such indeterminate melanocytic lesions (large nevus vs
small melanoma) should not be readily subjected to diagnos-
tic FNAB.46Figure 3. A 42 year old woman was evaluated for a partially amelanotic choro
evaluation including CT scans of the chest, abdomen, and pelvis and mammo
completely excluded based upon clinical examination, a diagnostic transvit
subretinal hemorrhage [black arrow head] and pocket of pre retinal hemo
melanoma (C). Reproduced with permission from: Biscotti CV, Singh AD. UveMelanoma: diagnostic
A number of studies have shown that FNAB has a diagnos-
tic accuracy rate of over 90%.4,23,25,43,49,50 Char observed
FNA to be accurate in both the diagnosis and cytologic
typing of uveal melanomas.51 Shields have also reported
similar results, with 26 of 27 (96%) patients diagnosed on
FNAB with uveal melanoma being subsequently proven to
have melanoma on enucleation.23
Regardless of the differential diagnosis, cytologists must
interpret the cellular features within the clinical context. This
emphasizes the importance of communication between
cytologists and ophthalmologists. We have found a stepwise
diagnostic approach for uveal melanoma very useful.50 Cytol-
ogists should first look for cytoplasmic melanin pigment
(Fig. 4A).50 Melanin has a finely granular cytoplasmic distribu-
tion that can be focal and inconspicuous. We have observed
melanin in 78% of uveal melanomas in our series.52 The spin-
dle type melanoma cell (Fig. 4B)50 is the next most helpful
diagnostic criterion in the differential diagnosis with metasta-
sis because the vast majority of uveal metastases are carcino-
mas, mostly from the breast and lung.53 These tumors have
an epithelioid appearance and cohesive cell clusters. Spindle
cell carcinomatous metastases occur rarely.54 Immunohisto-idal mass OD (A). Her past medical history was non contributory. Systemic
graphy were negative. As possibility of choroidal metastasis could not be
real FNAB was performed (B). Note biopsy site [arrow], and localized
rrhage [white arrowhead]). FNA determined the mass to be choroidal
al metastases. Monographs in clinical cytology 2012; 21: 17–30.46
Figure 4. Presence of melanin and spindle cells are helpful cytologic diagnostic features. This uveal melanoma cell has melanin and is spindle shaped (A).
A spindle cell without melanin (B). Though rarely needed, immunohistochemical stains for melanoma markers, such as HMB45 illustrated here, can help
identify amelanotic melanoma cells (C). Reproduced with permission from: Biscotti CV, Singh AD. Uveal melanoma: diagnostic features. Monographs in
clinical cytology 2012; 21: 44–54.50
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roendocrine markers, and melanoma markers such as S100
and HMB45 can be helpful especially in cases of amelanotic
epithelioid cell melanoma (Fig. 4C).44,50
Melanoma: prognostic
Significant progress has been made in understanding of
the role of tumor histopathology, cytogenetics, and gene
expression patterns in predicting metastatic potential of
uveal melanoma (Fig. 5).55 Therefore, it has become increas-
ingly common to perform FNAB for prognostic purposes.
Fluorescence in situ hybridization (FISH), single-nucleotide
polymorphism (SNP) array, and gene expression profiling
(GEP) are frequently employed to assess metastatic risk.55
Intraocular lymphoma
Vitrectomy is required to diagnose primary vitreo retinal
lymphoma (ophthalmic variant of primary central nervous
system lymphoma) as it predominantly manifests as lympho-Figure 5. FISH using directly labeled fluorescent probes to the alpha-
centromeric region of chromosome 3 (CEP3) (SpectrumOrange) and the
3p25 locus (SpectrumGreen) with 4’,6-Diamidino-2 Phenylindole (DAPI)
counterstain is illustrated, demonstrating eusomy (disomy) of chromo-
some 3 (two orange signals) and deletion of the 3p25 locus (one green
signal). Reproduced with permission from: Turell ME, Tubbs RR, Biscotti
CV, Singh AD. Uveal melanoma: prognostication. Monographs in clinical
cytology 2012; 21: 55–60.55cytic infiltration of the vitreous.56 Cellular assessment is often
done in conjunction with ancillary studies, such as immunohis-
tochemistry or flow cytometry.57–59
Retinoblastoma and other retinal tumors
FNAB in cases of retinoblastoma or suspected retinoblas-
toma is considered to be a relative contraindication because
the risk of seeding of the tumor outside the eye is of partic-
ular concern.23,25,60,61 FNAB is recommended only in highly
selected cases of retinal tumors where there is a true diag-
nostic dilemma after all possible clinical investigations includ-
ing an opinion by an expert ophthalmic oncologist have been
obtained.61 Even so, the FNAB should be done by a modified
technique, wherein the needle is passed parallel to the visual
axis through the peripheral cornea, anterior chamber, periph-
eral iris, zonules (avoiding the lens), and into the suspicious
area.23
Orbital tumors
Role of orbital FNAB particularly for lacrimal gland tumors,
lymphoproliferative tumors, and metastatic lesions of the or-
bit is discussed elsewhere.62
Limitations
False negative biopsy
Limited cellularity can compromise the diagnostic poten-
tial of ophthalmic aspirate samples.5,63 In our series of 30
unpublished cases, 4 cases had limited cellularity. In one pa-
tient whose biopsy was read as ‘‘negative’’ subsequently
underwent incisional biopsy which revealed a uveal schwan-
noma.64 Augsburger in his case series, reported 2 false neg-
atives out of 5 totally negative reports.21
A negative cytologic diagnosis of malignancy should not
be considered unequivocal proof that an intraocular malig-
nancy does not exist.21 Others have also echoed similar views
regarding unreliability of negative diagnoses.25,45 Care must
be given to important practical considerations to reduce like-
lihood of a negative biopsy (Table 1).
False positive biopsy
Overall concordance between histologic findings and
cytologic diagnosis (in experienced centers) may be as high
Table 1. Practical considerations to reduce likelihood of a false negative ophthalmic fine needle aspiration biopsy (Personal recommendations).
Factors Guidance
Tumor size Avoid small tumors (less than 2.5 mm in height)
Needle size Avoid thinner needle (such as 30 gauge)
Aspiration Avoid plunger retraction once aspiration has been completed
Sample Avoid dry smears. Rinse the needle into a transport medium flushing the contents of the needle and syringe several times
Experience Practice on enucleated globes to familiarize with the techniques
Personnel Experienced cytopathologist is essential
Reproduced with permission from: Singh AD, Pelayes DE, Brainard JA, Biscotti CV. History, indications, techniques, and limitations. Monographs in clinical cytology 2012; 21: 1–9.5
Figure 6. Hemorrhage. Localised sub retinal hemorrhage at the biopsy site (A, appearance 2 days later). Note total resolution of hemorrhage at 4 weeks
(B). Reproduced with permission from: Singh AD, Pelayes DE, Brainard JA, Biscotti CV. History, indications, techniques and limitations. Monographs in
clinical cytology 2012; 21: 1–9.5
Figure 7. Retinal detachment. Pre biopsy appearance (A). Spontaneous closure of the retinal break created during trans vitreal fine needle aspiration
biopsy (B, arrow). Reproduced with permission from: Singh AD, Pelayes DE, Brainard JA, Biscotti CV. History, indications, techniques and limitations.
Monographs in clinical cytology 2012; 21: 1–9.5




The risk of needle tract seeding associated with FNAB de-
creases with the diameter of the needle. A study performed
at the Karolinska Institute in Sweden followed 656 patients
who underwent cervical lymph node diagnostic FNAB for a
metastatic malignancy using 22 gauge needles. These pa-
tients were followed for 5 years and none of the patients
showed evidence of local tumor growth. Also, in experimen-
tal models65 and in studies of survival rates of patients with
breast cancer66 and thyroid nodules,67 there were no differ-
ences noted between groups with and without FNAB. In
ophthalmic FNAB, the number of tumor cells in the scleral
tracts of the 30 gauge needle was lower when the needletransversed aqueous or vitreous.68 Even so, the number of
cells was not enough to cause tumor growth in an experimen-
tal model.68 In more than 200,000 cases of transocular FNAB
in the literature, there has been no evidence of local or sys-
temic spread of tumor cells with the use of 25 gauge or smal-
ler diameter needles.5,21,23,41,43,68–70
Hemorrhage
The most frequent complications are localized subretinal
and vitreous hemorrhage at the biopsy site.23,35 The hemor-
rhage is controlled by gentle pressure on the globe immedi-
ately after withdrawal of the needle. The hemorrhages
typically resolve within a few weeks (Fig. 6).5
Retinal detachment
The retinal break created when a subretinal tumor is biop-
sied transvitreally almost never leads to rhegmatogenous
122 A.D. Singh, C.V. Biscottiretinal detachment. The break is sealed by the blood clot at
the biopsy site (Fig. 7).5
Endophthalmitis
FNAB induced endophthalmitis is extremely rare as oph-
thalmic FNAB is performed under sterile conditions. Only 2
such cases have been reported.5,44,47
Conclusions
The vast majority of intraocular tumors can be diagnosed
based on clinical examination and ocular imaging studies,
which obviate the need for diagnostic ophthalmic FNAB.
Overall, diagnostic accuracy of ophthalmic FNAB is high
but limited cellularity can compromise the diagnostic poten-
tial of ocular aspirate samples.
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